Orphan drug considerations in Health Technology Assessment in eight European countries
Abstract
Health Technology Assessment (HTA) is used to assess the value of new technologies and by producing coverage recommendations it indirectly controls the uptake of new technologies in many European countries. While HTA generally relies on a robust estimation of the clinical cost-effectiveness of a new technology, the clinical and economic evidence required for this purpose is often not available for Orphan Drugs (ODs), partly because of challenges related to the recruitment of patients to participate in clinical trials. A number of European HTA agencies have started to implement specific policies to address the challenges related to evidence requirements for the case of ODs. In this study, we map out the policies currently in place in eight European countries regarding HTA and its application to the case of ODs and explore the implications these policies have for coverage decisions.
Keywords
Full Text:
PDFReferences
Kanavos P, Nicod E, van den Aardweg S, Pomedli S. The impact of health technology assessments: an international compari- son. Euro observer. 2010;12(4):1-7.
Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU. European Parliament, Brussels 2011 [accessed 2013 April 22nd]. Available from: http://www.europarl.europa.eu/document/ activities/cont/201201/20120130ATT36575/20120130ATT36575EN.pdf.
EC. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal
products. Official Journal of the European Communities L. 2000;18(1).
Kanavos P, Nicod E. What Is Wrong with Orphan Drug Policies? Suggestions for Ways Forward. Value Health. 2012;15(8):1182- 4.
Nicod E, Kanavos P. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implica- tions for coverage decisions. Health Policy. 2012;108(2-3):167-77.
EURORDIS. Survey: Patients’ Access to Orphan Drugs in Europe 2010 [accessed 2013 April 30th]. Available from: http:// www.eurordis.org/content/survey-patients%E2%80%99-access-orphan-drugs-europe.
EMINET. Initial investigation to assess the feasibility of a coordinated system to access orphan medicines 2011 [accessed 2013 April 30th]. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/access_orphans_initialin- vest_052011_en.pdf.
Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: Opportu- nities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20-6.
Garau M, Mestre-Ferrandiz J. Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries.
OHE Briefing. 2009;52.
Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6(1):42.
G-BA. The benefit assessment of pharmaceuticals in accordance with the German Social Code, Book Five (SGB V), section 35a: GB-A; 2011 [accessed 2013 October 9th]. Available from: http://www.english.g-ba.de/benefitassessment/information/ faq/#3.
Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7(1):74.
Roos J, C. P. , Hyry HI, Cox T, M. Orphan drug pricing may warrant a competition law investigation. BMJ. 2010;341:c6471.
European Commission. The Ernst and Young study on the Clinical Added Value of Orphan Drugs (CAVOD) 2011 [accessed 2014 March 28th]. Available from: http://ec.europa.eu/eahc/news/news96.html.
European Commission. Platform on Access to Medicines in Europe - Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP) 2013 [accessed 2013 August 6th]. Available from: http://ec.europa.eu/enterprise/ sectors/healthcare/files/docs/orphans_report_en.pdf.
Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97(2-3):173-9.
Collier J. The Pharmaceutical Price Regulation Scheme. BMJ. 2007;334(7591):435-6.
Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329(7459):224-7.
NICE. Appraising Orphan Drugs 2006 [accessed 2013 April 22nd]. Available from: http://www.nice.org.uk/aboutnice/
whoweare/seniormanagementteam/seniormanagementteammeetings/2005/12july2005/appraising_orphan_drugs.jsp
Barham L. Orphan Medicines: Special treatment required? : 2020 Health; 2012 [accessed 2013 June 10th]. Available from:
http://www.2020health.org/2020health/Publications/publications-2012/Orphan-Drugs.html.
AGNSS. Advisory Group for National Specialised Services (AGNSS): NHS; 2013 [accessed 2013 June 10th]. Available from:
http://www.specialisedservices.nhs.uk/info/agnss.
Hendriksz CJ. Transfer of high cost drugs to NICE risks fragmentation of care of rare diseases. BMJ. 2012;345.
NICE. Developing NICE highly specialised technologies: National Institute for Health and Care Excellence; 2013 [accessed 2013 June 10th]. Available from: http://www.nice.org.uk/aboutnice/howwework/devhst/DevelopingNICEHighlySpecial- isedTechnologies.jsp.
NICE. Developing NICE single technology appraisals (STAs): National Institute for Health and Care Excellence; 2013 [ac- cessed 2013 June 10th]. Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_sin- gle_technology_appraisals.jsp.
NICE. Interim Process and Methods of the Highly Specialised Technologies Programme: National Institute for Health and Care Excellence; 2013 [accessed 2013 June 10th]. Available from: http://www.nice.org.uk/media/188/49/HST_combined_ Interim_Process_and_Methods_FINAL_31_May_2013.pdf.
Ferrario A and Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. EMiNet, Brussels, Belgium 2013 [accessed April 2014 April 1st]. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/
mea_report_en.pdf
NHSC. Priority setting: managing individual funding requests: Primary Care Trust Network; The NHS Confederation; 2008 [accessed 2013 June 10th]. Available from: http://www.nhsconfed.org/Publications/Documents/Priority%20setting%20 managing%20individual%20funding%20requests.pdf.
NHSCB. Interim Commissioning Policy: Individual funding requests: NHS Commissioning Board; 2013 [accessed 2013 June 10th]. Available from: http://www.england.nhs.uk/wp-content/uploads/2013/04/cp-03.pdf.
Department of Health. The UK Strategy for Rare Diseases 2013 [accessed 2014 March 27th] Available from: https://www.
gov.uk/government/uploads/system/uploads/attachment_data/file/260562/UK_Strategy_for_Rare_Diseases.pdf
NHS England. UK Strategy for Rare Diseases. NHS England Statement of Intent 2014 [accessed 2014 March 27th] Available from: http://www.england.nhs.uk/wp-content/uploads/2014/02/rare-dis-stat-intent.pdf
Ministère de l’économie, des finances et de l’industrie, Ministere de l’enseignement supérieur et de la recherche, Ministère des solidarités et de la cohésion sociale, Ministère du travail, de l’emploi et de la santé. Plan national maladies rares 2011- 2014 2011 [accessed 2013 May 9th]. Available from: http://www.orpha.net/actor/Orphanews/2011/doc/Plan_national_mal- adies_rares.pdf.
Ministère de la santé et de la protection sociale, Secrétariat d’Etat aux personnes handicapés. French National Plan for Rare Diseases 2005-2008 “Ensuring equity in the access to diagnosis, treatment and provision of care” 2004 [accessed 2013 May 9th]. Available from: http://www.orpha.net/actor/EuropaNews/2006/doc/French_National_Plan.pdf.
Remuzat C, Toumi M, Falissard B. New drug regulations in France: what are the impacts on market access? Part 1-Overview
of new drug regulations in France. Journal of Market Access & Health Policy. 2013;1:20891.
AFAR. Publication de la LFSS 2010 [accessed 2014 February 27th]. Available from: http://www.afar.asso.fr/index.
php?option=com_view&Itemid=34&articleid=116&table=mos_ydea_article_articles&task=view.
Natz A, Campion M-G. Pricing and reimbursement of innovative pharmaceuticals in France and the new healthcare reform.
Farmeconomia. Health economics and therapeutic pathways. 2012;13(2):47-58.
PPRI. Pharmaceutical Pricing and Reimbursement Information project - Germany 2008 [accessed 2013 May 9th]. Available from: http://whocc.goeg.at/Literaturliste/Dokumente/CountryInformationReports/Germany_PPRI_2008.pdf.
Hörn H, Nink K, McGauran N, Wieseler B. Early benefit assessment of new drugs in Germany – Results from 2011 to 2012.
Health Policy. 2014 [accessed February 27th]. Available from: http://dx.doi.org/10.1016/j.healthpol.2013.12.008.
ASDReports. European Payers Push Back on Orphan Drug Prices: ASD Reports; 2013 [accessed 2013 October 14th]. Avail- able from: www.asdreports.com/news.asp?pr_id=1952.
GKV. AMNOG - evaluation of new pharmaceutical: GKV Spitzenverband; [accessed 2013 June 10th]. Available from:
http://www.gkv-spitzenverband.de/english/statutory_health_insurance/amnog
evaluation_of_new_pharmaceutical/am-
nog
evaluation_of_new_pharmaceutical_1.jsp.
IQWiG. General Methods - version 4.0 of 23.09.2011: IQWiG; 2011 [accessed 2013 May 10th]. Available from: www.iqwig.
de/download/General_Methods_4-0.pdf.
CIPE. DELIBERAZIONE 1 febbraio 2001 2001 [accessed 2013 November 15th]. Available from: www.gazzettaufficiale.
it/eli/id/2001/03/28/001A3188/sg.
Bernardi A, Pegoraro R. The ethics of off-label use of drugs: oncology pharmacy in Italy. J Clin Pharm Ther. 2008;33: 95-99.
PLANO NAZIONALE MALATTIE RARE 2013-2016 Ministero della Salute; 2012 [accessed 2013 July 12th]. Available from: http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3296&area=Malattie%20rare&menu=vuoto.
WHO. Poland - Health system review. Health Systems in Transition. 2011;13(8).
AOTM. Guidelines for conducting Health Technology Assessment (HTA) - Version 2.1 2009 [accessed 2013 June 13th].
Available from: http://www.aotm.gov.pl/assets/files/wytyczne_hta/2009/09.06.29_wytyczne_HTA_eng_MS.pdf.
PPRI. Pharmaceutical Pricing and Reimbursement Information - Poland 2007 [accessed 2013 May 10th]. Available from:
http://whocc.goeg.at/Literaturliste/Dokumente/CountryInformationReports/Poland_PPRI_2007.pdf.
Ozieranski P, McKee M, King L. The politics of health technology assessment in Poland. Health Policy.
;108:178–193.
SMC. Product Assessment Timelines 2013/2013: Scottish Medicines Consortium; [accessed 2013 May 7th].
Available from: http://www.scottishmedicines.org.uk/Submission_Process/Submission_Guidance_and_Tem- plates_for_Industry/Timelines_2012_2014.pdf.
SMC. Scottish Executive: NHS HDL 60 2003 [accessed 2013 May 7th]. Available from: http://www.sehd.scot.nhs.uk/mels/
hdl2003_60.pdf.
Cairns J. Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excel- lence compared. Health Policy. 2006;76(2):134-43.
CMO/CPO. Guidance to furhter strengthen the safe and effective use of new medicines across the NHS in Scotland: Scot- tish Government; 2012 [accessed July 1st 2013]. Available from: http://www.scottishmedicines.org.uk/About_SMC/Policy_ Statements/CMO_2012_01_Guidance.pdf
SMC. Orphan Drugs 2007 [accessed 2013 May 10th]. Available from: http://www.scottishmedicines.org.uk/About_SMC/ Policy_Statements/Orphan_Drugs.
SMC. SMC Modifiers used in Appraising New Medicines: Scottish Medicines Consortium; 2012 [accessed 2013 April 24th].
Available from: http://www.scottishmedicines.org.uk/About_SMC/Policy_Statements/SMC_Modifiers_used_in_Appraising_ New_Medicines.
SMC. Patient Access Schemes. [accessed 2014 March 27th]. Available from: http://www.scottishmedicines.org.uk/Submis-
sion_Process/Submission_Guidance_and_Templates_for_Industry/Patient-Access-Schemes.
SG. The availability of new medicines for patients in Scotland: The role of the Scottish Medicines Consortium (SMC): Scot- tish Government; 2013 [accessed 2013 June 10th]. Available from: http://www.scotland.gov.uk/Resource/0042/00421354. pdf.
The Scottish Government. New medicines review published 2013 [accessed 2013 May 13th]. Available from: http://www. scotland.gov.uk/News/Releases/2013/05/review0305.
The Scottish Government. New Medicines Reviews 2013 / 2013 [accessed 2013 May 13th]. Available from: http://www. scotland.gov.uk/Publications/2013/05/2542.
The Scottish Government. Implementation Plan for Rare Diseases in Scotland [accessed 2014 March 27th] Available from:
http://www.scotland.gov.uk/Topics/Health/Services/RareDiseases.
ISCIII. Últimas monografías de cada centro / unidad: Instituto de Salud Carlos III; 2013 [accessed 2013 June 14th]. Avail- able from: http://publicaciones.isciii.es/index.jsp.
Agencia Estatal Boletín Oficial del Estado. Real Decreto-ley 16/2012, de 20 de abril, de medidas urgentes para garantizar la sostenibilidad del Sistema Nacional de Salud y mejorar la calidad y seguridad de sus prestaciones 2012 [accessed 2014 February 19th]. Available from: http://www.boe.es/diario_boe/txt.php?id=BOE-A-2012-5403.
Martínez Vallejo M, Ferré de la Peña P, Guilló Izquierdo MJ, Lens Cabrera C. PHIS Pharma Profile Spain 2010: Pharma- ceutical Health Information System; 2010 [accessed 2013 May 7th]. Available from: http://whocc.goeg.at/Literaturliste/ Dokumente/CountryInformationReports/Spain_PHIS_PharmaProfile_2010.pdf.
Sorenson C. The role of HTA in coverage and pricing decisions: a cross-country comparison. Euro observer. 2009;11(1):1-4.
Redman T, Köping Höggård M. PPRI Pharma Profile Sweden 2007: Commissioned by the European Commission, Direc- torate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth; 2007 [ac- cessed 2013 May 7th]. Available from: http://whocc.goeg.at/Literaturliste/Dokumente/CountryInformationReports/Swe- den_PPRI_2007.pdf
Willis M, Persson U, Zoellner Y, Gradl B. Reducing uncertainty in value-based pricing using evidence development agree- ments. Appl Health Econ Health Policy. 2010;8(6):377-86.
Anell A, Persson U. Reimbursement and clinical guidance for pharmaceuticals in Sweden. Eur J Health Econ. 2005;6(3):274-9.
Hugosson K, Engstrom A. PHP67 THRESHOLD VALUE FOR A QALY-CORRELATION WITH DISEASE SEVERITY AND DECISION UNCERTAINTY. Value Health. 2008;11(3):A49.
SKL. Nya läkemedelsterapier - NLT: Sveriges Kommuner og Landsting; 2010 [accessed 2013 October 30th]. Available from:
http://www.skl.se/vi_arbetar_med/halsaochvard/lakemedel/nlt.
Regeringskansliet. Pris, tillgång och service - fortsatt utveckling av läkemedels- och apoteksmarknaden: Swedish Govern- ment; 2012 [accessed 2013 June 10th]. Available from: http://www.regeringen.se/sb/d/15773/a/202565.
NHS England. The Cancer Drugs Fund [accessed 2014 March 7th]. Available from: http://www.england.nhs.uk/ourwork/ pe/cdf.
Department of Health. Impact Assessment of Proposal for a Cancer Drug Fund 2010 [assessed 2014 March 14th]. Avail- able from: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/ dh_digitalassets/@dh/@en/documents/digitalasset/dh_120930.pdf.
AIFA. La ricerca indipendente sui farmaci [accessed 2014 March 7th]. Available from: http://www.agenziafarmaco.gov.it/it/ content/la-ricerca-indipendente-sui-farmaci-0.
EHESP, de Sauniere A. L’accès aux médicaments orphelins en France: entre besoins des patients, soutien à la recherche et politique de prix 2012 [accessed 2014 February 25th]. Available from: http://fulltext.bdsp.ehesp.fr/Ehesp/Memoires/ Phisp/2012/de_sauniere.pdf.
